Loading...
A standard 6-month course of adjuvant chemotherapy after curative surgery has been shown to provide a survival benefit for patients with stage III colon cancer. However, the risk for toxicity — in particular, sensory neuropathy from oxaliplatin, contained in standard adjuvant regimens — has highlighted the need for a shorter-duration treatment.
Investigators now report the results of a prospective, pooled analysis of 6 international trials comparing 3 versus 6 months of adjuvant chemotherapy for stage III colon cancer. Nearly 13,000 patients received chemotherapy with either CAPOX (capecitabine and oxaliplatin) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin). Most patients (59%) had lower-risk disease (T1, T2, or T3 N1); 41% had higher…